Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases.
Helen R GosseltJette A van LintLeanne J KossePhyllis I SpulsHarald E VonkemanSander W TasFrank HoentjenMichael T NurmohamedBart J F van den BemtMartijn Bastiaan Adriaan van DoornNaomi T JessurunPublished in: Expert opinion on drug safety (2023)
Sex differences in the frequency and nature of ADRs, but not in ADR burden, exist during treatment with adalimumab and etanercept in patients with inflammatory rheumatic diseases. This should be taken into consideration when investigating and reporting results on ADRs and when counseling patients in daily clinical practice.
Keyphrases
- adverse drug
- rheumatoid arthritis
- juvenile idiopathic arthritis
- clinical practice
- end stage renal disease
- electronic health record
- oxidative stress
- ejection fraction
- emergency department
- rheumatoid arthritis patients
- newly diagnosed
- peritoneal dialysis
- disease activity
- physical activity
- ulcerative colitis
- smoking cessation
- hidradenitis suppurativa
- hiv testing
- patient reported